Welcome to the international HTA database

Showing [16732 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	Agency for Care Effectiveness (ACE)	Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025	Agency for Care Effectiveness (ACE)	Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025	NIHR Health Technology Assessment programme	Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025	NIHR Health Technology Assessment programme	Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025	NIHR Health Technology Assessment programme	Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025	NIHR Health Technology Assessment programme	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025	National Institute for Health and Care Excellence (NICE)	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025	National Institute for Health and Care Excellence (NICE)	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025	Agency for Care Effectiveness (ACE)	Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025	Agency for Care Effectiveness (ACE)	Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025	Agency for Care Effectiveness (ACE)	Antibacterial envelope for implantable neurostimulator infection control
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025	NIHR Health Technology Assessment programme	Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025	Technology Assessment at SickKids (TASK)	A micro-costing and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025	Agency for Care Effectiveness (ACE)	EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025	Agency for Care Effectiveness (ACE)	Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025	NIHR Health Technology Assessment programme	High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025	National Institute for Health and Care Excellence (NICE)	Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025	National Institute for Health and Care Excellence (NICE)	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025	National Institute for Health and Care Excellence (NICE)	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025	National Institute for Health and Care Excellence (NICE)	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025	National Institute for Health and Care Excellence (NICE)	Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025	National Institute for Health and Care Excellence (NICE)	Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025	National Institute for Health and Care Excellence (NICE)	Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025	National Institute for Health and Care Excellence (NICE)	Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025	NIHR Health and Social Care Delivery Program	Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025	NIHR Health and Social Care Delivery Program	Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025	NIHR Health Technology Assessment programme	A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025	NIHR Health and Social Care Delivery Program	The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Alpha-blocking medication before removal of indwelling urinary catheters
2025	NIHR Health and Social Care Delivery Program	Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025	NIHR Health and Social Care Delivery Program	Organising general practice for care homes: a multi-method study
2025	HTA South	[Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025	NIHR Health and Social Care Delivery Program	Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025	NIHR Health and Social Care Delivery Program	Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025	NIHR Health Technology Assessment programme	Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
2025	NIHR Health Technology Assessment programme	Supporting self-management with an internet intervention for low back pain in primary care: a RCT (SupportBack 2)
2025	NIHR Health and Social Care Delivery Program	Formulating outputs from a mixed-methods study of access to general practice: a series of collaborative stakeholder workshops
2025	NIHR Health Technology Assessment programme	Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025	NIHR Health Technology Assessment programme	Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis
2025	NIHR Health Technology Assessment programme	A personalised health intervention to maintain independence in older people with mild frailty: a process evaluation within the HomeHealth RCT
2025	NIHR Health Services and Delivery Research programme	Multiple Symptoms Study 3 – an extended-role general practitioner clinic for patients with persistent physical symptoms: a randomised controlled trial
2025	NIHR Health Services and Delivery Research programme	The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY)
2025	Health Technology Wales (HTW)	Implantable tibial neuromodulation devices for treatment of urge urinary incontinence
2025	Health Technology Wales (HTW)	Use of advanced electrosurgical bipolar vessel sealing systems during hysterectomy compared to other methods for control of bleeding
2025	Health Technology Wales (HTW)	At-home video monitoring for the diagnosis and management of epilepsy
2025	Health Technology Wales (HTW)	Permanent implant brachytherapy devices for the treatment of locally advanced, unresectable pancreatic cancer
2025	Health Information and Quality Authority (HIQA)	National guidelines for the budget impact analysis of health technologies in Ireland
2025	Health Information and Quality Authority (HIQA)	National guidelines for the economic evaluation of health technologies in Ireland
2025	National Institute for Health and Care Excellence (NICE)	Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 801
2025	National Institute for Health and Care Excellence (NICE)	12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2025	National Institute for Health and Care Excellence (NICE)	Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025	National Institute for Health and Care Excellence (NICE)	Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1046
2025	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. NICE technology appraisal guidance 1050
2025	National Institute for Health and Care Excellence (NICE)	Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1049
2025	National Institute for Health and Care Excellence (NICE)	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable. NICE technology appraisal guidance 1048
2025	NIHR Health Technology Assessment programme	A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2025	NIHR Health Technology Assessment programme	Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map
2025	NIHR Health Technology Assessment programme	Experiences of support to return to work after stroke: longitudinal case studies from RETAKE trial
2025	NIHR Health Technology Assessment programme	Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Exagamglogene autotemcel (Exa-cel, Casgevy®)
2025	NIHR Health Technology Assessment programme	Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prediction models in dental care - basis for the National Board of Health and Welfare’s mission to develop a national model for risk assessment in dental care]
2025	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[ADHD and driving performance]
2025	Health Sciences Institute in Aragon (IACS)	Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Dedicated staff for placement of indwelling urinary catheters
2025	NIHR Health Technology Assessment programme	The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks
2025	NIHR Health Technology Assessment programme	Management of diarrhoea in patients with stable ulcerative colitis with low FODMAP diet, amitriptyline, ondansetron or loperamide: the MODULATE RCT
2025	NIHR Health Services and Delivery Research programme	The implementation of safety management systems in healthcare: a systematic review and international comparison
2025	Scottish Health Technologies Group (SHTG)	Stability of prostate specific antigen (PSA) in blood samples
2025	National Institute for Health and Care Excellence (NICE)	Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. NICE interventional procedures guidance 802
2025	National Institute for Health and Care Excellence (NICE)	Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
2025	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy. NICE technology appraisal guidance 1040
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1039
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over. NICE technology appraisal guidance 1038
2025	National Institute for Health and Care Excellence (NICE)	Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over. NICE technology appraisal guidance 1033
2025	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025	National Institute for Health and Care Excellence (NICE)	Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025	National Institute for Health and Care Excellence (NICE)	Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over. NICE technology appraisal guidance 1044
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025	NIHR Health Technology Assessment programme	Understanding the effectiveness and underlying mechanisms of lifestyle modification interventions in adults with learning disabilities: a mixed-methods systematic review
2025	NIHR Health Services and Delivery Research programme	Optimisation of the deployment of automated external defibrillators in public places in England
2025	NIHR Health Services and Delivery Research programme	Clinical and cost-effectiveness of paramedics working in general practice: a mixed-methods realist evaluation
2025	NIHR Health Technology Assessment programme	Establishing palliative care research partnerships in Northern Ireland
2025	NIHR Health Technology Assessment programme	Learnings from the establishment and delivery of the UK Collaborative Paediatric Palliative Care Research Network
2025	NIHR Health Technology Assessment programme	Interventions that challenge established and accepted clinical practice: lessons learnt from a process evaluation of the STOP-APE trial
2025	NIHR Health Services and Delivery Research programme	Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences
2025	NIHR Health Services and Delivery Research programme	Understanding and addressing factors affecting carers’ mental health during end-of-life caregiving: synopsis of meta synthesis of literature and stakeholder collaboration
2025	NIHR Health Services and Delivery Research programme	Intersecting factors of disadvantage and discrimination and their effect on daily life during the coronavirus pandemic: the CICADA-ME mixed-methods study
2025	NIHR Health Technology Assessment programme	Stepping into day treatment approach versus inpatient treatment for adults with anorexia nervosa: the DAISIES RCT
2025	NIHR Health Services and Delivery Research programme	Improving the experience of health services for trans and gender-diverse young people and their families: an exploratory qualitative study